Company profile: Algernon Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceutical R&D, in-licensing, and commercialization, advancing NP-120 (Ifenprodil) investigated for chronic cough and idiopathic pulmonary fibrosis, NP-251 (Repirinast) repurposed for chronic kidney disease, and AP-188 (DMT), a naturally occurring psychedelic compound explored for stroke and traumatic brain injury.
Products and services
- AP-188 (DMT): Investigational, naturally occurring psychedelic compound being explored as a treatment for stroke and traumatic brain injury by Algernon Pharmaceuticals
- NP-120 (Ifenprodil): Investigational candidate studied for chronic cough and idiopathic pulmonary fibrosis, originally approved in Japan and South Korea for vertigo
- NP-251 (Repirinast): Repurposed compound originally developed for asthma, now being repurposed for chronic kidney disease by Algernon Pharmaceuticals
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Algernon Pharmaceuticals
Actimis Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics for respiratory and inflammatory disorders; a start-up biopharmaceutical company spun off from Bayer Healthcare AG's respiratory diseases therapeutic research portfolio, founded by Dr. Kevin Bacon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Actimis Pharmaceuticals company profile →
Sirtris Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on discovering and developing proprietary, orally available small molecule drugs to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirtris Pharmaceuticals company profile →
SynDevRx
HQ: United States
Website
- Description: Provider of polymer-based drug conjugates for oncology, including evexomostat (SDX-7320), a polymer-drug conjugate that releases a fumagillol derivative in vivo to target cancer and systemic metabolic hormone dysfunction. Sponsors clinical trials across various cancer types, provides an expanded access program, and advances a pipeline focused on cancers sensitive to metabolic hormones, leveraging metabo-oncology and polymer-drug conjugation to improve safety and activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SynDevRx company profile →
Arch Biopartners
HQ: Canada
Website
- Description: Provider of product acquisition and development for sale to pharmaceutical and industrial companies, with a focus on LSALT peptide (Metablok), a drug candidate that inhibits DPEP1 to target acute organ inflammation in the lungs, liver, and kidneys, including a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide for cardiac surgery–associated acute kidney injury.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Biopartners company profile →
Herborium
HQ: United States
Website
- Description: Provider of botanical therapeutics that develops, licenses, and markets proprietary botanical-based medicinal products. Offerings include AcnEase, a herbal acne and rosacea treatment; the Virtual Institute for Natural and Complementary Medicine, an educational platform for integrative medicine; the Kamasutra Spirits product line; and Herborium Botanical Therapeutics addressing dermatological needs and sexual disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Herborium company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Algernon Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Algernon Pharmaceuticals
2.2 - Growth funds investing in similar companies to Algernon Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Algernon Pharmaceuticals
4.2 - Public trading comparable groups for Algernon Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →